Colonization of Artificial Substrates at Dauphin Island, Alabama: A Comparison of Balanus (Cirripedia), Membranipora tenuis (Bryozoa), and Conopeum tenuissimum (Bryozoa) Settlement in 1999-2000 and 2010-12

Glass slides were used as artificial substrates to collect settling bryozoan and barnacle larvae during two collection periods, in 1999–2000 and 2010–12. This study follows up a previous report of Balanus settlement in Mobile Bay and now includes two bryozoan species. Slides were immersed at the Dauphin Island Sea Lab (Alabama) for 1 wk each month for 17–18 mo in each study, and then collected for staining and counting. The bryozoans Conopeum tenuissimum and Membranipora tenuis were both present in 1999–2000, though in 2010–12 C. tenuissimum was rarer and only six organisms were observed. In general the bryozoan colonization period extended throughout the spring, summer, and fall, with peak settlement in May–Aug. Barnacle cyprids and metamorphed stages colonized the substrates in July–Sept. and Feb.– March in 1999–2000, but in 2010–12 they were present in the summer and fall months and did not have a Feb.–March settlement. Colonization by both bryozoans and barnacles correlated statistically with temperature, and M. tenuis correlated negatively with salinity as its colonization density increased following the decreased salinity in the spring. In 1999–2000 only M. tenuis correlated with temperature. This study reports settlement periods for these invertebrates in Alabama and provides new data for colonization studies in Mobile Bay. Additionally, we document the successful colonization of substrates by these invertebrates immediately following the Deepwater Horizon oil spill

Affective and Motivational Responses to 3D Body Imaging

Common body weight and composition testing has been shown to impact emotional, motivational, and behavioral responses. Three-dimensional body imaging is a relatively new technology to be utilized in medical and fitness settings to provide detailed body image feedback to the patient or client, while encouraging motivation to control body weight, fat, and shape. However, such responses to 3D body imaging have not been examined. To examine the acute affective and motivational responses to 3D body imaging (Fit3D) in a sample of college-aged women (N = 32), classified as either normal weight (NW; n = 13) or overweight/obese (OWOB; n = 19). Positive and negative affect were assessed with the Positive (PA) and Negative Affect (NA) Schedule (PANAS; range: 1-5), and one item assessed motivation to lose weight (range: 1-10). These variables were assessed immediately before and after a single 3D body imaging session. Participants had 1-minute to examine their 3D body scan, and then continued to examine their scan during all post-measures. Overall, PA did not change pre- to post-scan (3.11 ± .98 to 3.18 ± 1.07, p \u3e .05), nor did NA (1.52 ± .58 to 1.63 ± .89, p \u3e .05). In addition, there was not a time by BMI (NW versus OWOB) interaction for both PA and NA. Overall, motivation to lose weight slightly increased (6.41 ± 2.78 to 7.09 ± 2.75, p = .001). There was not an interaction of time by BMI, with both groups increasing over time. However, there was a between-subjects effect with OWOB holding higher pre-motivation to lose weight than NW participants (7.63 versus 4.62, respectively; p \u3c .01). Within the present sample of college-aged women, a 3D body image scanning session did not appear impact PA or NA responses, but did produce a slight increase in motivation to lose body weight in participants classified as NW or OWOB. This research provides foundational insight to future research and the use of this novel technology for health behavior change in fitness and clinical settings

Effects of a 3D Body Imaging Trigger on Self-Perceived Attractiveness, Self-conscious Emotions and Coping

Novel technologies currently being utilized in fitness and clinical settings, such as 3D body scans, are proposed to act as a trigger or spark for weight control behavior. However, other weight-related triggers in women have been shown to produce variation in emotional and weight control responses, and there is limited research on their impact. The purpose of the study was to examine the acute effect of 3D body imaging system (Fit3D) on self-conscious emotions (guilt, shame, pride) and body weight-related coping in a sample of college-aged women (N = 30) classified as normal weight (NW, n = 12) or overweight/obese (OWOB, n = 18). To this end, the Body and Appearance-related Self-conscious Emotions Scale (BASES; range: 1-5) and the WEIGHTCOPE (range: 1-7) were used to assess self-conscious emotions and intention to utilize 10 different weight-related coping strategies following a single 3D body scanning session. Body fat percentage (BF%) was assessed via Dual-energy x-ray absorptiometry (DXA). Following the 3D scan, participants experienced low to moderate feelings of guilt (3.18 ± .99), shame (2.67 ± 1.05), authentic pride (2.68 ± .96), and hubristic pride (2.49 ± .87). Significant differences (p \u3c .05) were found between participants classified as NW or OWOB, respectively, in shame (2.11 ± .76 vs. 3.05 ± 1.07), guilt (2.82 ± .85 vs. 3.43 ± 1.02), and authentic pride (3.10 ± .78 vs. 2.39 ± .98). Increasing physical activity and self-regulation, eating healthier, and positively reframing the situation were the highest rated coping responses (M = 5.23 to 6.25). Differences were found between BMI groups for intention to cope by suppressing appetite (NW = 2.68 ± 1.05, OWOB = 3.56 ± 1.02; t = 2.24, p \u3c .05), supplement use (NW = 1.14 ± .22, OWOB = 1.85 ± 1.28; t = 2.30, p \u3c .05), and a trend for camouflaging body (NW = 2.70 ± .51, OWOB = 3.14 ± .99, t = 1.57, p = .06). Feelings of shame were correlated with intention to camouflage body (r = .46, p = .01), while authentic pride trended toward a negative correlation with suppressing appetite (r = -.31), camouflaging (r = -.35), and supplement use (-.34). In conclusion, an acute 3D body image scan session was shown to produce variation in self-conscious emotions (shame, guilt, and pride) and coping choices between NW and OWOB participants. These individual differences should be taken into consideration to better accommodate healthy behavior change following 3D imaging use

Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease.

BACKGROUND: The use of mycophenolate mofetil (MMF) in autoimmune disease is often limited by adverse effects. In this single-centre, open label, parallel design study, we investigated whether enteric-coated mycophenolate sodium (MS) is better tolerated and therefore more efficacious than MMF in primary systemic vasculitis (PSV) and systemic lupus erythematosus (SLE). METHODS: Forty patients with vasculitis or systemic lupus erythematosus (SLE) due to commence MMF for active disease or remission maintenance were randomized to receive either 1440 mg/day MS or 2000 mg/day MMF (18 PSV, 2 SLE per group) in addition to corticosteroids. Random allocation was performed by minimization for age, diagnosis and renal function using a computer algorithm. Twenty-five were treated for active disease (5 first-line therapy, 20 salvage therapy) and 15 for remission maintenance. The composite primary end point was treatment failure and/or drug intolerance over 12 months. Treatment failure was defined as failure to achieve remission by 6 months or disease relapse and treatment intolerance was defined as inability to tolerate and maintain the target dose of MS or MMF within 12 months. RESULTS: Forty patients were included in the analyses. MS was associated with a lower primary end point rate [hazard ratio (HR) 0.37; 95% CI 0.17-0.80; P = 0.012] (11/20, 55% patients) compared with MMF (17/20, 85% patients). Treatment failure alone was less common in the MS group (HR 0.28; 95% CI 0.095-0.82; P = 0.020), although drug intolerance did not differ between groups (HR 0.53; 95% CI 0.20-1.42; P = 0.21). Despite randomization, patients in the MMF group may have had a higher baseline risk for treatment failure; more MMF patients had refractory disease and granulomatosis with polyangiitis (Wegener's). A glomerular filtration rate (GFR) ≤40 mL/min was associated with intolerance. Serious adverse events were common (55% MMF and 45% MS patients). CONCLUSIONS: No differences in treatment tolerance were observed between the MS and MMF groups. Despite similar treatment intolerance, MS was associated with improved efficacy in PSV and SLE compared with MMF. However, baseline group imbalances in factors potentially affecting remission and relapse may have influenced the results. Treatment intolerance was common and strongly associated with low GFR. Further treatment trials are warranted to investigate the effect of GFR on mycophenolic acid pharmacokinetics and clinical outcomes (ISRCTN83027184; EUDRACT 2005-002207-16; Funding Novartis UK)

Laser-heated high-temperature NMR - a time-resolution study

International audienc

Toward actionable practice parameters for dual diagnosis : Principles of assessment and management for co-occurring psychiatric and intellectual/developmental disability

PURPOSE OF REVIEW: Although treatment algorithms and parameters for best practice are readily available for all major syndromes of psychiatric impairment, the occurrence of psychiatric syndromes in individuals with intellectual and developmental disability (IDD) invokes serious contextual challenges for interpretation of symptoms, diagnosis, and optimization of treatment, both for clinicians and for the service sectors in which care and support of individuals with IDD are delivered. Recognizing that there exist very few definitive resources for best practice under the circumstance of this form of dual diagnosis, the Missouri Department of Mental Health convened an expert panel to conduct a focused review and synthesis of the relevant scientific literature from which to develop guidance in the form of decision support to clinicians. This article summarizes the findings for three of the most common and impairing clusters of psychiatric symptoms that co-occur with IDD-aggression, depression, and addictions. RECENT FINDINGS: Individuals with IDD are at high risk for the development of psychiatric symptoms (PS), which often manifest uniquely in IDD and for which evidence for effective intervention is steadily accruing. Interventions that are commonly implemented in the IDD service sector (e.g., functional communication training and positive behavioral support planning) are capable of mitigating severe behavioral impairment, yet rarely invoked when dual diagnosis patients are seen in the psychiatric service sector. Conversely, state-of-the-art interventions for traumatic stress, pharmacotherapy, and psychotherapy have proven capable of improving behavioral impairments in IDD but are typically restricted to the psychiatric service sector, where there exist significant barriers to access for patients with IDD, including limitations imposed by diagnostic eligibility and practitioner experience. Bridging these gaps in knowledge and clinical capacity across the respective IDD and PS service sectors should be of very high priority in strategizing the care and support of IDD patients with serious co-occurring psychiatric conditions

Impact of Systematic Errors in Sunyaev-Zel'dovich Surveys of Galaxy Clusters

Future high-resolution microwave background measurements hold the promise of detecting galaxy clusters throughout our Hubble volume through their Sunyaev-Zel'dovich (SZ) signature, down to a given limiting flux. The number density of galaxy clusters is highly sensitive to cluster mass through fluctuations in the matter power spectrum, as well as redshift through the comoving volume and the growth factor. This sensitivity in principle allows tight constraints on such quantities as the equation of state of dark energy and the neutrino mass. We evaluate the ability of future cluster surveys to measure these quantities simultaneously when combined with PLANCK-like CMB data. Using a simple effective model for uncertainties in the cluster mass-SZ flux relation, we evaluate systematic shifts in cosmological constraints from cluster SZ surveys. We find that a systematic bias of 10% in cluster mass measurements can give rise to shifts in cosmological parameter estimates at levels larger than the $1\sigma$ statistical errors. Systematic errors are unlikely to be detected from the mass and redshift dependence of cluster number counts alone; increasing survey size has only a marginal effect. Implications for upcoming experiments are discussed.Comment: 12 pages, 6 figures; accepted to JCAP; revised to match submitted versio

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.

BACKGROUND: Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However, after rituximab some patients develop hypogammaglobulinaemia. METHODS: We performed a single centre retrospective review of 177 patients with multisystem autoimmune disease receiving rituximab between 2002 and 2010. The incidence, severity and complications of hypogammaglobulinaemia were investigated. RESULTS: Median rituximab dose was 6 g (1-20.2) and total follow-up was 8012 patient-months. At first rituximab, the proportion of patients with IgG <6 g/L was 13% and remained stable at 17% at 24 months and 14% at 60 months. Following rituximab, 61/177 patients (34%) had IgG <6 g/L for at least three consecutive months, of whom 7/177 (4%) had IgG <3 g/L. Low immunoglobulin levels were associated with higher glucocorticoid doses during follow up and there was a trend for median IgG levels to fall after ≥ 6 g rituximab. 45/115 (39%) with IgG ≥ 6 g/L versus 26/62 (42%) with IgG <6 g/L experienced severe infections (p=0.750). 6/177 patients (3%) received intravenous immunoglobulin replacement therapy, all with IgG <5 g/L and recurrent infection. CONCLUSIONS: In multi-system autoimmune disease, prior cyclophosphamide exposure and glucocorticoid therapy but not cumulative rituximab dose was associated with an increased incidence of hypogammaglobulinaemia. Severe infections were common but were not associated with immunoglobulin levels. Repeat dose rituximab therapy appears safe with judicious monitoring